S. Hurtado et al., REGULAR PRODUCTION OF INFECTIVE SPOROZOITES OF PLASMODIUM-FALCIPARUM AND PLASMODIUM-VIVAX IN LABORATORY-BRED ANOPHELES-ALBIMANUS, Annals of tropical medicine and parasitology, 91(1), 1997, pp. 49-60
One of the major constraints for studies on the sporogonic cycle of th
e parasites causing human malaria, and on the protective efficacy of p
re-erythrocytic vaccines, is the scarcity of laboratory-reared Anophel
es mosquitoes as a source of infective sporozoites. The aim of the pre
sent study was to reproduce the life-cycles of Plasmodium falciparum a
nd P. vivax in the laboratory and so develop the ability to produce in
fective sporozoites of these two species regularly under laboratory co
nditions. Colonized Anopheles albimanus, of Buenaventura and Tecojate
strains, were infected by feeding either on Plasmodium-infected blood,
from human patients or experimentally inoculated Aotus monkeys, or on
gametocytes of the P. falciparum NF-54 isolate grown in vitro. The mo
nkeys were infected with the blood stages of a Colombian P. vivax isol
ate and then, after recovery, with the Santa Lucia strain of P. falcip
arum from El Salvador. Although both of the mosquito strains used were
successfully infected with both parasite species, the Buenaventura st
rain of mosquito was generally more susceptible to infection than the
Tecojate strain, and particularly to infection with the parasites from
the patients, who lived where this strain of mosquitoes was originall
y isolated. Monkeys injected intravenously with the P. vivax sporozoit
es produced in the mosquitoes developed patent sexual and asexual para
sitaemias; the gametocytes that developed could then be used to infect
mosquitoes, allowing the development of more sporozoites. However, ex
perimental infections failed to establish after the P. falciparum spor
ozoites were used to inoculate monkeys. The ability to reproduce the c
omplete life cycle of P. vivax in the laboratory, from human to mosqui
to and then to monkey, should greatly facilitate many studies on vivax
malaria and on the efficacy of candidate malaria vaccines. The availa
bility of the sporogonic cycles of P. falciparum from three different
sources should also permit a variety of biological studies.